N
Nuwellis
Biotech & Life Sciences · Brooklyn Park, United States · Founded 1998 · IPO 2012
CHF Solutions focuses on an innovative cardiac assist therapy to treat patients with heart failure and related conditions MoreLess
Nuwellis, Inc. is a medical device company that specializes in developing and commercializing products for the treatment of fluid overload, a condition that affects patients with heart failure and other cardiac diseases. The company's flagship product is the Aquadex FlexFlow system, a minimally invasive device that removes excess fluid from the body. The Aquadex system is used in hospitals and other clinical settings to treat patients who are not responding to diuretic drugs.
Nuwellis' business model is based on the sale of its Aquadex FlexFlow system and related disposable products. The company sells its products through a direct sales force in the United States and through a network of distributors in other countries. Nuwellis' target customers include hospitals, clinics, and other healthcare providers that treat patients with heart failure and other cardiac diseases.
Keywords: medical devices, fluid overload, heart failure, cardiac diseases, Aquadex FlexFlow, minimally invasive, hospitals, clinics, healthcare providers, direct sales
Talent graph
Nuwellis's talent
Source: Dealroom Talent Intelligence.
Investors
2 investors on Nuwellis's cap table
Sourced from Dealroom's funding and investor records.

Global footprint
Where Nuwellis has talent and traffic
team presence
Market sentiment
What the market is saying about Nuwellis
An AI-synthesized read of the highest-engagement posts about Nuwellis on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nuwellis on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.